Progress in the Pathogenesis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus
- PMID: 36078885
- PMCID: PMC9456588
- DOI: 10.3390/jcm11174955
Progress in the Pathogenesis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus
Abstract
Neuropsychiatric systemic lupus erythematosus (NPSLE) has a broad spectrum of subtypes with diverse severities and prognoses. Ischemic and inflammatory mechanisms, including autoantibodies and cytokine-mediated pathological processes, are key components of the pathogenesis of NPSLE. Additional brain-intrinsic elements (such as the brain barrier and resident microglia) are also important facilitators of NPSLE. An improving understanding of NPSLE may provide further options for managing this disease. The attenuation of neuropsychiatric disease in mouse models demonstrates the potential for novel targeted therapies. Conventional therapeutic algorithms include symptomatic, anti-thrombotic, and immunosuppressive agents that are only supported by observational cohort studies, therefore performing controlled clinical trials to guide further management is essential and urgent. In this review, we aimed to present the latest pathogenetic mechanisms of NPSLE and discuss the progress in its management.
Keywords: management; neuropsychiatric lupus erythematosus; novel targeted therapies; pathogenesis; systemic lupus erythematosus.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Neuropsychiatric Systemic Lupus Erythematosus: A 2021 Update on Diagnosis, Management, and Current Challenges.Cureus. 2021 Sep 14;13(9):e17969. doi: 10.7759/cureus.17969. eCollection 2021 Sep. Cureus. 2021. PMID: 34667659 Free PMC article. Review.
-
Advances in the diagnosis, pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus.Curr Opin Rheumatol. 2020 Mar;32(2):152-158. doi: 10.1097/BOR.0000000000000682. Curr Opin Rheumatol. 2020. PMID: 31895125 Free PMC article. Review.
-
Neuropsychiatric lupus: new mechanistic insights and future treatment directions.Nat Rev Rheumatol. 2019 Mar;15(3):137-152. doi: 10.1038/s41584-018-0156-8. Nat Rev Rheumatol. 2019. PMID: 30659245 Free PMC article. Review.
-
Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review.Semin Arthritis Rheum. 2021 Feb;51(1):49-71. doi: 10.1016/j.semarthrit.2020.12.004. Epub 2020 Dec 17. Semin Arthritis Rheum. 2021. PMID: 33360230
-
Mouse models, antibodies, and neuroimaging: Current knowledge and future perspectives in neuropsychiatric systemic lupus erythematosus (NPSLE).Front Psychiatry. 2023 Mar 8;14:1078607. doi: 10.3389/fpsyt.2023.1078607. eCollection 2023. Front Psychiatry. 2023. PMID: 36970286 Free PMC article. Review.
Cited by
-
Cognitive impairment in systemic lupus erythematosus patients: prevalence and its association with quality of life.BMC Rheumatol. 2025 Mar 28;9(1):37. doi: 10.1186/s41927-025-00486-y. BMC Rheumatol. 2025. PMID: 40148993 Free PMC article.
-
Advancements in Immunology and Microbiology Research: A Comprehensive Exploration of Key Areas.Microorganisms. 2024 Aug 14;12(8):1672. doi: 10.3390/microorganisms12081672. Microorganisms. 2024. PMID: 39203514 Free PMC article. Review.
-
New-onset acute psychosis as a manifestation of lupus cerebritis following concomitant COVID-19 infection and vaccination: a rare case report.BMC Psychiatry. 2023 Jun 12;23(1):419. doi: 10.1186/s12888-023-04924-4. BMC Psychiatry. 2023. PMID: 37308940 Free PMC article.
-
A child with recurrent headache, fever and diffuse meningeal enhancement on MRI.Clin Rheumatol. 2024 Oct;43(10):3249-3252. doi: 10.1007/s10067-024-07030-2. Epub 2024 Aug 11. Clin Rheumatol. 2024. PMID: 39127821 Review.
-
Neuropsychiatric Systemic Lupus Erythematosus: Molecules Involved in Its Imunopathogenesis, Clinical Features, and Treatment.Molecules. 2024 Feb 6;29(4):747. doi: 10.3390/molecules29040747. Molecules. 2024. PMID: 38398500 Free PMC article. Review.
References
-
- Li M., Wang Y., Zhao J., Wang Q., Wang Z., Tian X., Zeng X. Chinese SLE Treatment and Research group (CSTAR) registry 2009–2019: Major clinical characteristics of Chinese patients with systemic lupus erythematosus. Rheumatol. Immunol. Res. 2021;2:43–47. doi: 10.2478/rir-2021-0001. - DOI - PMC - PubMed
-
- Liang M.H., Corzillius M., Bae S.C., Lew R.A., Fortin P.R., Gordon C., Isenberg D., Alarcón G.S., Straaton K.V., Denburg J., et al. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599–608. doi: 10.1002/1529-0131(199904)42:43.0.Co;2-f. - DOI - PubMed
-
- Hanly J.G., Li Q., Su L., Urowitz M.B., Gordon C., Bae S.C., Romero-Diaz J., Sanchez-Guerrero J., Bernatsky S., Clarke A.E., et al. Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2020;72:67–77. doi: 10.1002/art.41070. - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources